On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
